|
|
About
The Berlin Center for Epidemiology and Health Research (ZEG Berlin: acronym for the German name: Zentrum für Epidemiologie & Gesundheitsforschung) was founded in 1990.
It has its roots in the first Epidemiology Research Centre for non-communicable diseases in Germany, i.e. the founding key persons of ZEG and many employees had rich experience in non-communicable disease epidemiology and prevention since the late 1960. Currently, the main focus of the institute is research in Pharmacoepidemiology and Drug Surveillance.
ZEG and ENCePP
We are a partner centre of the ENCePP scientific network which is coordinated by the European Medicines Agency. We are dedicated to excellence in research by adhering to the ENCePP Guide on Methodological Standards and promoting scientific independence and transparency. We register studies in the ENCePP E-Register of Studies, a publicly accessible resource for the registration of pharmacoepidemiological and pharmacovigilance studies.
Short description . . . more
ZEG Berlin is an independent (private) research institute with a main focus on pharmacoepidemiology and outcomes research, particularly on drug safety and risk management/ minimization (see organizational chart)
Specialty: large multinational observational studies based on existing networks of experienced collaborators/physicians and their patients in Europe, North America or elsewhere that can be completed or amended on short notice if desirable. Epidemiological /pharmacoepidemiological studies can be setup fast and cost-efficiently for all indications of new and also older substances which are already longer in the market. It is even possible saddling up on already running studies..
The understanding as independent research institute implies that our institute is responsible for full service, i.e. the development of study design and all study materials, execution of field work with physicians and patients, data management, analyses, and publication in peer-reviewed journals. Studies are preferably based on direct patient contact: Cohort studies (register and active surveillance studies both physician- and patient-based), case-control studies, and cross-sectional surveys in all parts of the world.
Keeping contact with thousands of patients over years is a specialty of ZEG. This includes all forms of face-to-face or other personal communications, e.g. also web-based interactions with patients or physicians.
The institute can provide full service including crisis management and legal advice based on fundamental experience, e.g. lawsuits.
Structure and scope . . . more
ZEG is affiliated with the globally operating Kantar (Healthcare) Group wich has over 40 offices throughout the Americas, Europe, Asia-Pacific, the Middle East and Africa.
ZEG is a center of expertise for pharmacoepidemiology/drug safety for Kantar Healthcare, respectively.
ZEG has performed or was involved in observational studies related to pharmacoepidemiology in over 20 countries in Europe, The Americas, Asia, and Africa.
In addition to conducting such studies the institute offers particular experience in multicenter descriptive & analytic pharmacoepidemiological or pharmacovigilance studies, and postmarketing active surveillance research (outcome studies), e.g. with networks of physicians or other institutions across Europe and in other parts of the world together with partners (see ZEG and its network).
Members of the institute are well experienced in leading study teams and/or collaborating with other centers in study teams over many years, i.e., functioning as principal investigator (PI) of many investigators in one country or as overall PI in a network of many investigators across countries.
ZEG also offers expert opinion for court cases and counseling in complex issues of drug safety, even in case of litigations - and has very successfully done so in the past.
Many publications in peer-reviewed journals emerged from our research. Since 1990 ZEG staff members have published over 200 publications and research reports in (inter-)national peer reviewed journals and have given approximately 150 oral presentations at national and international conferences (see Publications).
The scope of our scientific staff meets the tasks to be fulfilled by ZEG. In house, many experts in Epidemiology/ Pharmacoepidemiology, Statistics, IT, Clinical Medicine and Pharmacology, Pharmacy, as well as Ethical, Legal and Regulatory expertise are available. Expertise in genetics/pharmocogenetics is only available via existing contacts in the network or collaborating research institutes, e.g, university departments.
In the past years, the ZEG has performed or was involved in drug safety/risk-benefit research in the following therapeutic/disease areas: cardiovascular diseases, disorders of the central nervous system, endocrine disorders, gynecology, malignant diseases, nutrition and blood, osteoporosis, pregnancy, psychiatry, renal impairment, urinary tract disorders.
|
|
| printversion 
| sitemap 
| © 2011 www.zeg-berlin.de